Please assess the completion status of the following clinical trial:

Trial Title: A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 to 80 years（including the critical value);~2. Acute ischemic stroke is diagnosed according to the WHO (World Health Organization) stroke diagnostic criteria, the symptoms of acute ischemic stroke are expected to be less than 4.5 hours after the time of acute ischemic stroke which is defined as the last time the patient functions well;~3. NIHSS score at the time of treatment: from 4 points to 25 points (including 4 points and 25 points);~4. From the signing of informed consent form to 3 months after treatment, fertile men and women of childbearing age should be absent of a birth plan and willing to take effective contraceptive measures;~5. Participants who can understand and follow the research process, voluntarily participate, and sign an informed consent form (informed consent is voluntarily signed by the person or legal representative).~Exclusion Criteria:~1. Known to be allergic to research drugs or similar ingredients, or materials used in imaging studies;~2. Weight \>120kg or \<45kg;~3. The timing of stroke symptoms is not known;~4. mRS score before stroke≥ 2 points;~5. NIHSS score 1a (level of consciousness) ≥ 2 points during screening;~6. Patients with intracerebral hemorrhage history;~7. CT/MRI imaging examination shows signs of intracranial hemorrhage or suspected subarachnoid hemorrhage despite CT/MRI imaging findings do not show abnormalities;~8. Severe cerebral trauma or stroke history or other severe traumas within 3 months;~9. Assessment of Intracranial tumor, arteriovenous malformation and aneurysm before admission;~10. Intracranial surgery, intraspinal surgery or other major surgeries within 3 months (based on the assessment of the investigators);~11. Patients with gastrointestinal or urinary system hemorrhage in recent 3 weeks;~12. Active visceral hemorrhage;~13. Assessment or with history of aortic arch dissection before admission;~14. Arterial puncture in 1 week which can not be oppressed;~15. Subjects who have an acute bleeding tendency, including but not limited to：1) a platelet count of less than 100 × 109 / L；2) application of low molecular heparin within 24 hours before onset ; 3) Using of thrombin inhibitors or factor Xa inhibitor within 48 hours before onset ; 4) application of oral anticoagulant drugs and with an INR \> 1.7 or PT\>15s;~16. Hypertension remains uncontrolled after active antihypertensive therapy, uncontrolled hypertension refers to a systolic blood pressure \>185 mmHg and/or a diastolic blood pressure \>110 mmHg;~17. Blood glucose \<50 mg/dl (equivalent to 2.78mmol/L) or \>400 mg/dl (equivalent to 22.2mmol/L);~18. Imaging (CT or MRI)shows large area cerebral infarction;~19. Severe liver damage, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis;~20. Bacterial endocarditis or pericarditis, acute pancreatitis at admission;~21. With history of gastrointestinal ulcers, esophageal varices, aneurysms, or arterial / venous malformations within 3 months before admission;~22. Patients who are unable to cooperate or are unwilling to cooperate with epileptic seizures, or other mental illnesses during stroke episodes;~23. Patients who are ready to go or have undergone endovascular treatment;~24. The restricted drug specified in the protocol or any drug that may interfere with the test results must be ingested or desired to continue to be ingested;~25. An expected survival time of no more than 1 year due to other diseases;~26. Patients who are participating in other trials or have participated in other trials within 30 days before randomization;~27. Pregnancy or lactation, or women who have a positive pregnancy test result;~28. The subject who is unsuitable for this study in the opinion of the investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- experimental group (Type: EXPERIMENTAL): Recombinant human tissue plasminogen kinase derivatives(r-PA) for injection: the first intravenous bolus injection of 18mg, after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time. Subjects were closely monitored during the treatment period and within 24 hours after administration.
- comparative group (Type: ACTIVE_COMPARATOR): Recombinant human tissue plasminogen activator (rt-PA) for injection: 0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours after administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).